NNC0165-1273

NNC0165-1273 (0.03-1 μmol/kg/d; subcutaneous injection; continuous infusion; 14 days) causes dose-dependent reductions in food intake, body weight, and fat mass in diet-induced obese male C57BL/6 mice, with the highest dose reducing fat mass by approximately 31%^[1].
NNC0165-1273 (0.04-1 μmol/kg; subcutaneous injection; single administration) potently inhibits ghrelin-induced feeding behavior in healthy male C57BL/6 mice, with the 0.04 μmol/kg dose almost completely blocking the orexigenic effect of ghrelin at 1 and 2 hours^[1].
Combined administration of NNC0165-1273 (0.08 µmol/kg/d; osmotic minipump; continuous infusion) and Semaglutide achieves a maximum body weight loss of 23.9% in diet-induced obese male Wistar rats, an effect superior to that observed with Roux-en-Y gastric bypass surgery in previous studies^[3].
Co-administration of NNC0165-1273 (0.04 µmol/kg/d; subcutaneous injection; continuous administration), NNC0165-0020 and Semaglutide (HY-114118) reduces the body weight of male Wistar rats with high-fat diet-induced obesity by a maximum of 20.5% and persistently decreases their preference for high-fat diet^[2].